Dendritic cells and immunity against cancer
Article first published online: 16 DEC 2010
© 2010 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 269, Issue 1, pages 64–73, January 2011
How to Cite
Palucka, K., Ueno, H., Fay, J. and Banchereau, J. (2011), Dendritic cells and immunity against cancer. Journal of Internal Medicine, 269: 64–73. doi: 10.1111/j.1365-2796.2010.02317.x
- Issue published online: 16 DEC 2010
- Article first published online: 16 DEC 2010
- Accepted manuscript online: 10 NOV 2010 11:52AM EST
- dendritic cells;
- T cells;
Palucka K, Ueno H, Fay J, Banchereau J (Baylor Institute for Immunology Research and Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; and Department of Gene and Cell Medicine and Department of Medicine, Immunology Institute, Mount Sinai School of Medicine, New York, NY, USA) Dendritic cells and immunity against cancer (Key Symposium). J Intern Med 2011; 269: 64–73.
Abstract. T cells can reject established tumours when adoptively transferred into patients, thereby demonstrating the power of the immune system for cancer therapy. However, it has proven difficult to maintain adoptively transferred T cells in the long term. Vaccines have the potential to induce tumour-specific effector and memory T cells. However, clinical efficacy of current vaccines is limited, possibly because tumours skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumour microenvironment. This can be achieved by exploiting the fast increasing knowledge about the dendritic cell (DC) system, including the existence of distinct DC subsets that respond differentially to distinct activation signals, (functional plasticity), both contributing to the generation of unique adaptive immune responses. We foresee that these novel cancer vaccines will be used as monotherapy in patients with resected disease and in combination with drugs targeting regulatory/suppressor pathways in patients with metastatic disease.